Leukemia Research
Volume 34, Issue 2 , Pages 166-172 , February 2010

BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients

  • Joon Ho Moon

      Affiliations

    • Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea
    • ,
  • Sang Kyun Sohn

      Affiliations

    • Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea
    • ,
  • Myung-Hoon Lee

      Affiliations

    • Department of Biochemistry, Kyungpook National University Hospital, Daegu, Republic of Korea
    • ,
  • Jun Ho Jang

      Affiliations

    • Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    • ,
  • Kihyun Kim

      Affiliations

    • Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    • ,
  • Chul Won Jung

      Affiliations

    • Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    • ,
  • Dong Hwan Kim

      Affiliations

    • Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea
    • Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Department of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Irwon-dong 50, Kangnam-gu, Seoul 135-710, Republic of Korea. Tel.: +82 2 3410 1768; fax: +82 2 3410 1754.

Received 12 March 2009 ,Revised 8 May 2009 ,Accepted 12 May 2009.

References 

  1. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci USA. 1996;93:14059–14064
  2. Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, Pla M, et al. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?. Cancer Res. 2007;67:8762–8771
  3. Peters R, Leyvraz S, Perey L. Apoptotic regulation in primitive hematopoietic precursors. Blood. 1998;92:2041–2052
  4. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, et al. bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood. 1992;79:1291–1298
  5. Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernardi S, et al. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica. 1995;80:98–102
  6. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9:159–165
  7. Casas S, Ollila J, Aventin A, Vihinen M, Sierra J, Knuutila S. Changes in apoptosis-related pathways in acute myelocytic leukemia. Cancer Genet Cytogenet. 2003;146:89–101
  8. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881–1892
  9. Lauria F, Raspadori D, Rondelli D, Ventura MA, Fiacchini M, Visani G, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia. 1997;11:2075–2078
  10. Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J, et al. Association of a novel regulatory polymorphism (−938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109:290–297
  11. Sohn SK, Kim DH, Kim JG, Lee NY, Suh JS, Lee KS, et al. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. Bone Marrow Transplant. 2004;34:63–68
  12. Sohn SK, Kim JG, Sung WJ, Kim DH, Suh JS, Lee KS, et al. Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization. J Clin Apheresis. 2003;18:186–189
  13. Sohn SK, Kim JG, Chae YS, Kim DH, Lee NY, Suh JS, et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis. 2003;18:10–15
  14. Tanaka S, Kant J, Reed JC. G to A polymorphism in the second exon of the BCL2 gene. Nucleic Acids Res. 1991;19:1964
  15. In:  Mitelman F editors. ISCN 1995: an international system for human cytogenetic, nomenclature 1995. Basel, Switzerland: S. Karger; 1995;
  16. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.. Blood. 1998;92:2322–2333
  17. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81:151–157
  18. Kondo S, Yin D, Morimura T, Oda Y, Kikuchi H, Takeuchi J. Transfection with a bcl-2 expression vector protects transplanted bone marrow from chemotherapy-induced myelosuppression. Cancer Res. 1994;54:2928–2933
  19. Guedez L, Suresh A, Tung F, Zucali J. Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2. Eur J Haematol. 1996;57:149–156
  20. Keith FJ, Bradbury DA, Zhu YM, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia. 1995;9:131–138
  21. Maung ZT, MacLean FR, Reid MM, Pearson AD, Proctor SJ, Hamilton PJ, et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol. 1994;88:105–109
  22. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999;5:1758–1766
  23. Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D, et al. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia. Leukemia. 2002;16:846–854
  24. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 1988;7:123–131
  25. Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol. 1993;13:3686–3697
  26. Park BL, Kim LH, Cheong HS, Cho HY, Kim EM, Shin HD, et al. Identification of variants in cyclin D1 (CCND1) and B-cell CLL/lymphoma 2 (BCL2). J Hum Genet. 2004;49:449–454
  27. Barrett JC, Fry B, Maller J, Daly M.J. . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265
  28. Stephens M, Smith NJ, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978–989

PII: S0145-2126(09)00258-6

doi: 10.1016/j.leukres.2009.05.009

Leukemia Research
Volume 34, Issue 2 , Pages 166-172 , February 2010

Article Tools

* Image Usage & Resolution